国际呼吸杂志
國際呼吸雜誌
국제호흡잡지
INTERNATIONAL JOURNAL OF RESPIRATION
2013年
19期
1481-1485
,共5页
哮喘%β2肾上腺素能受体%多态性%单倍型%3’非翻译区poly-C重复序列
哮喘%β2腎上腺素能受體%多態性%單倍型%3’非翻譯區poly-C重複序列
효천%β2신상선소능수체%다태성%단배형%3’비번역구poly-C중복서렬
Asthma%β2-adrenergic receptor%Polymorphisms%Haplotype%3' untranslated region poly-C repeat sequence
过去有关β2肾上腺素能受体基因(ADRB2)多态性的研究重点集中在编码区的多态性,这些多态性可能与哮喘的发生、表型及治疗反应相关,但是研究结果不完全一致.近年来大量研究发现,不仅仅是编码区,5 '和3’非翻译区的多态性同样能改变β2肾上腺素能受体(β2AR)的功能并影响着哮喘的治疗反应等,应同时对β2-AR基因中所有的变异即完整的单倍型进行识别和分析.现综述近来对ADRB2基因编码区、5’和3'非翻译区多态性的研究新进展,特别是3’非翻译区poly-C重复序列的长度的变异可能对哮喘患者的肺功能和对β2AR激动剂的治疗反应具有重要作用.
過去有關β2腎上腺素能受體基因(ADRB2)多態性的研究重點集中在編碼區的多態性,這些多態性可能與哮喘的髮生、錶型及治療反應相關,但是研究結果不完全一緻.近年來大量研究髮現,不僅僅是編碼區,5 '和3’非翻譯區的多態性同樣能改變β2腎上腺素能受體(β2AR)的功能併影響著哮喘的治療反應等,應同時對β2-AR基因中所有的變異即完整的單倍型進行識彆和分析.現綜述近來對ADRB2基因編碼區、5’和3'非翻譯區多態性的研究新進展,特彆是3’非翻譯區poly-C重複序列的長度的變異可能對哮喘患者的肺功能和對β2AR激動劑的治療反應具有重要作用.
과거유관β2신상선소능수체기인(ADRB2)다태성적연구중점집중재편마구적다태성,저사다태성가능여효천적발생、표형급치료반응상관,단시연구결과불완전일치.근년래대량연구발현,불부부시편마구,5 '화3’비번역구적다태성동양능개변β2신상선소능수체(β2AR)적공능병영향착효천적치료반응등,응동시대β2-AR기인중소유적변이즉완정적단배형진행식별화분석.현종술근래대ADRB2기인편마구、5’화3'비번역구다태성적연구신진전,특별시3’비번역구poly-C중복서렬적장도적변이가능대효천환자적폐공능화대β2AR격동제적치료반응구유중요작용.
Previous studies of association of beta 2 adrenergic receptor gene (β2-AR) with bronchial asthma was focused in the coding region polymorphisms,these polymorphisms may be associated with the asthmatic susceptivity,phenotype and response to treatment.But there are many inconsistent results,and these differences could not be fully explained by β2-AR gene coding region and the 5'untranslated region polymorphism.In recent years a large number of studies have found not only the coding region,5'and 3' untranslated region polymorphisms can also change the β2-AR function and affect treatment response in asthma.All variants that complete haplotypes on the β2-AR gene should be identified and analyzed.This article reviews the recent development of β2 AR gene coding region,5'and 3' untranslated region polymorphisms,especially the 3'untranslated region of poly-C repeat length variation on patients with asthma plays an important role on pulmonary function and β2-AR agonist treatment response.